Literature DB >> 25716672

Uptake of non-invasive prenatal testing (NIPT) and impact on invasive procedures in a tertiary referral center.

Gwendolin Manegold-Brauer1, C Berg, A Flöck, A Rüland, U Gembruch, A Geipel.   

Abstract

PURPOSE: The introduction of non-invasive prenatal testing (NIPT) by isolation of cell-free fetal DNA from maternal blood is a new diagnostic option in prenatal care. The aim of the study was to investigate the algorithm of prenatal testing before and after the introduction of NIPT in a tertiary referral center and to investigate the influence of NIPT on the frequency of invasive procedures.
METHODS: Retrospective data analysis was conducted of all singleton pregnancies that presented for first trimester screening 17 months before and after the introduction of NIPT (n = 2271). Women were categorized into three risk groups: low risk for trisomy 21 (<1:1000), intermediate risk (1:101-1:1000) and high risk (≥1:100). The choice of diagnostic testing after FTS was analyzed.
RESULTS: 1093 (group 1) presented before and 1178 (group 2) after the introduction of NIPT. The rate of high-risk patients was equal in both groups (14.4 vs. 15.4 %). No differences were found with regard to invasive testing (11.6 vs. 11.3 %). NIPT was chosen by 3.7 % (44/1178) in group 2. Of those with NIPT, 72.7 % had a risk estimate of <1:100, but 90.9 % were ≥35 years old. The rate of NIPT among high-risk patients with a normal ultrasound examination was 25 %.
CONCLUSION: At present, NIPT is chosen mainly for reassurance by patients not considered to be at high risk. In the high-risk group, NIPT can be offered if the ultrasound examination is normal and the risk is high due to maternal age or serum screening alone. The rate of invasive testing was not reduced in this selected population.

Entities:  

Mesh:

Year:  2015        PMID: 25716672     DOI: 10.1007/s00404-015-3674-5

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  7 in total

1.  Count-based size-correction analysis of maternal plasma DNA for improved noninvasive prenatal detection of fetal trisomies 13, 18, and 21.

Authors:  Li Zhang; Qian Zhu; He Wang; Shanling Liu
Journal:  Am J Transl Res       Date:  2017-07-15       Impact factor: 4.060

2.  Trends in the use of prenatal testing services for fetal aneuploidy in Ontario: a descriptive study.

Authors:  Tianhua Huang; Shelley Dougan; Mark Walker; Christine M Armour; Nan Okun
Journal:  CMAJ Open       Date:  2018-10-05

3.  Noninvasive prenatal testing in routine clinical practice for a high-risk population: Experience from a center.

Authors:  Guijie Qi; Jianping Yi; Baosheng Han; Heng Liu; Wanru Guo; Chong Shi; Lirong Yin
Journal:  Medicine (Baltimore)       Date:  2016-10       Impact factor: 1.889

Review 4.  Non-invasive prenatal testing for fetal chromosome abnormalities: review of clinical and ethical issues.

Authors:  Jean Gekas; Sylvie Langlois; Vardit Ravitsky; François Audibert; David Gradus van den Berg; Hazar Haidar; François Rousseau
Journal:  Appl Clin Genet       Date:  2016-02-04

5.  Considering medical risk information and communicating values: A mixed-method study of women's choice in prenatal testing.

Authors:  An Chen; Henni Tenhunen; Paulus Torkki; Seppo Heinonen; Paul Lillrank; Vedran Stefanovic
Journal:  PLoS One       Date:  2017-03-29       Impact factor: 3.240

6.  In-house genetic counseling increases the detection of abnormal karyotypes-a 26-year experience in prenatal diagnosis in a single tertiary referral hospital in Poland.

Authors:  Julia Bijok; Anna Kucińska-Chahwan; Diana Massalska; Alicja Ilnicka; Grzegorz Panek; Tomasz Roszkowski
Journal:  J Assist Reprod Genet       Date:  2020-05-19       Impact factor: 3.412

7.  First Trimester Screening - Current Status and Future Prospects After Introduction of Non-invasive Prenatal Testing (NIPT) at a Tertiary Referral Center.

Authors:  Adeline Walter; Corinna Simonini; Ulrich Gembruch; Anne Flöck; Brigitte Strizek; Annegret Geipel
Journal:  Geburtshilfe Frauenheilkd       Date:  2022-09-06       Impact factor: 2.754

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.